Palbociclib (PD-0332991; from Pfizer) was first approved by the FDA on February 3, 2015 as the first-line treatment for advanced post-menopausal ER+, HER2-negative breast cancer, in combination with letrozole [30]. The gene discussed is ERBB2; the disease is breast carcinoma.